Gestational and Placental Disorders Choriocarcinoma

Slide 1 · Choriocarcinoma

Gestational and placental disorders

Malignant trophoblastic neoplasia: morphology, spread and clinical relevance

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning objectives

After this session, you should be able to:

Define gestational choriocarcinoma and identify its pregnancy-associated origins.

Recognize the biphasic trophoblastic histology, lack of villi, and destructive invasion.

Correlate bleeding, HCG behavior, metastatic pattern, and treatment response.

Slide 3 · Gestational trophoblastic disease: The context

GTD comprises trophoblastic proliferations with distinct biological behavior.

Major categories include hydatidiform moles, invasive mole, choriocarcinoma, PSTT, and ETT.

Choriocarcinoma belongs to the frankly malignant end of this spectrum.

Its distinction from molar lesions depends strongly on villous morphology and invasion.

Slide 4 · GTD spectrum: Morphologic categories

Separate diagnostic categories: The boxes do not denote required sequential stages.

Hydatidiform mole

Invasive mole

Choriocarcinoma

Slide 5 · Two trophoblastic populations

The normal trophoblast provides the histologic vocabulary.

Cytotrophoblast is a component of chorionic villous trophoblast.

Syncytiotrophoblast is the second trophoblastic component described in villi.

Choriocarcinoma contains proliferating malignant forms of both populations.

Slide 6 · Trophoblastic cellular forms: Schematic

SCHEMATIC — not a histologic specimen

Biphasic cellular concept

Cytotrophoblast: Mononuclear cells.

Syncytiotrophoblast: Multinucleated cellular component.

The schematic is illustrative; Morphology must be assessed on genuine sections.

Slide 7 · Definition: Gestational choriocarcinoma

A malignant trophoblastic neoplasm originating from pregnancy.

The antecedent pregnancy may have been normal or abnormal.

Origin may follow an intrauterine or extrauterine pregnancy.

The neoplasm is invasive and capable of early disseminated disease.

Slide 8 · Four pathology signatures

The defining findings should be interpreted together.

Proliferating malignant cytotrophoblast and syncytiotrophoblast.

No chorionic villi within the tumor.

Prominent hemorrhage and necrosis.

Destructive invasion, including involvement of blood vessels.

Slide 9 · Frequency in the United States

1 in

20,000–30,000 pregnancies

Gestational choriocarcinoma is uncommon.

This is the frequency reported for U.S. Pregnancies.

The denominator is pregnancies, not molar pregnancies.

Slide 10 · Association with complete mole

50%

Of choriocarcinomas

Antecedent complete hydatidiform mole is the largest single group.

The percentage describes antecedents among choriocarcinomas.

It does not mean that half of all complete moles become malignant.

Slide 11 · Antecedent pregnancy: Reported distribution

Antecedent pregnancy

Share

Interpretation

Complete hydatidiform mole

50%

Largest preceding category

Spontaneous abortion

25%

May arise after pregnancy loss

Normal pregnancy

Approximately 22%

May follow an apparently normal gestation

Ectopic / intraplacental

Remainder

Less frequent contexts

Proportions are those; Rounding means the remainder is not independently measured here.

Slide 12 · Antecedent pregnancy is not always a mole

Gestational origin does not imply a preceding molar diagnosis.

Choriocarcinoma may follow spontaneous abortion.

It may emerge after a normal pregnancy.

An ectopic pregnancy may be the antecedent event.

Slide 13 · Why complete mole is important

Complete mole has a documented relationship to subsequent malignant disease.

It is androgenetic: Nuclear genetic material is paternally derived.

A 2.5% risk of subsequent choriocarcinoma after complete mole.

It also cites a 15% risk of persistent or invasive mole.

Slide 14 · Genetic basis of common complete mole

The common mechanism produces diploid 46,XX complete mole.

Enucleated / “empty” ovum

Single sperm fertilization

Paternal genome duplication

Slide 15 · Complete versus partial mole: Key context

Complete mole

Paternally derived nuclear genome.

Usually diploid; No embryonic development.

More established association with choriocarcinoma.

Partial mole

Usually dispermic triploidy.

Fetal development may occur.

Not typically linked to postmolar choriocarcinoma.

This is antecedent-lesion context, not the morphology of choriocarcinoma.

Slide 16 · Distinguish absolute and conditional risk

Two different denominators must never be conflated.

About 50% of choriocarcinomas follow complete mole (antecedent distribution).

About 2.5% of patients with complete mole develop choriocarcinoma (subsequent risk).

These figures answer different epidemiologic questions.

Slide 17 · Invasive mole versus choriocarcinoma

Invasive mole

Hydropic chorionic villi infiltrate myometrium.

Proliferating cytotrophoblast and syncytiotrophoblast line villi.

Can show vascular invasion and distant embolization.

Choriocarcinoma

Malignant trophoblast without chorionic villi.

Marked hemorrhage and tumor necrosis.

Destructive invasion and wide metastasis are characteristic.

Presence or absence of chorionic villi is a decisive morphologic distinction.

Slide 18 · Nongestational choriocarcinoma

A rare morphologic counterpart develops outside a pregnancy origin.

Can arise from germ cells in the ovary or mediastinum.

Looks morphologically identical to gestational choriocarcinoma.

Has a different genomic ancestry and generally less favorable prognosis.

Slide 19 · Gestational versus nongestational lineage

Nongestational tumors lack paternally derived DNA.

Choriocarcinoma histology

Assess genomic origin

Paternal DNA present → gestational

Slide 20 · Paternally derived DNA as a discriminator

Microscopic appearance alone may not establish pregnancy origin.

Gestational choriocarcinoma contains paternal DNA.

Nongestational choriocarcinoma lacks paternal-derived DNA.

Genomic ancestry is the distinguishing feature.

Slide 21 · Why lineage classification matters

Gestational origin

Related to prior pregnancy.

Paternal DNA can establish origin.

Often highly responsive to chemotherapy.

Nongestational origin

Rare ovarian / mediastinal germ-cell origin.

No paternally derived DNA.

More difficult to treat; Less favorable outlook.

Slide 22 · Gross pattern: Invasive hemorrhagic mass

SCHEMATIC — not a histologic specimen

Hemorrhage / necrosis schematic

Destructive hemorrhagic neoplasia

Soft, fleshy, yellow-white tumor.

Extensive hemorrhage often dominates the gross appearance.

Large pale necrotic areas may coexist with viable tumor.

Slide 23 · The tumor may appear yellow-white

Gross viable tumor and breakdown must be distinguished.

The mass as soft and fleshy.

Yellow-white neoplastic areas may be present.

Necrosis and hemorrhage commonly obscure the gross background.

Slide 24 · Hemorrhage and necrosis are characteristic

SCHEMATIC — not a histologic specimen

Hemorrhage / necrosis schematic

A hallmark of aggressive growth

Large hemorrhagic regions are common.

Pale necrotic areas are also frequent.

A gross impression alone is insufficient for definitive cellular diagnosis.

Slide 25 · Gross pattern and clinical bleeding

The destructive lesion explains its hemorrhagic presentation.

Myometrial and vascular invasion underlie tissue disruption.

Tumor-associated hemorrhage parallels irregular vaginal bleeding.

The amount of viable tumor may be reduced by extensive necrosis.

Slide 26 · Biphasic trophoblastic proliferation

SCHEMATIC — not a histologic specimen

Two malignant trophoblast populations

Proliferating cytotrophoblasts.

Proliferating syncytiotrophoblasts.

Both populations form the defining tumor-cell composition.

Slide 27 · Cytotrophoblast is one tumor component

Recognition requires careful inspection of cellular phenotype.

Cytotrophoblast contributes a recognizable mononuclear population.

It coexists with malignant syncytiotrophoblast.

The tumor is not described as a purely single-cell population.

Slide 28 · Syncytiotrophoblast is the second component

The tumor reproduces trophoblastic cellular differentiation.

Syncytiotrophoblast is part of the malignant proliferative component.

Its coexistence with cytotrophoblast creates the biphasic pattern.

High HCG values are commonly associated with gestational disease.

Slide 29 · Chorionic villi are absent

SCHEMATIC — not a histologic specimen

Absence is a positive diagnostic clue

The neoplasm is composed of malignant trophoblasts.

Hydropic chorionic villi are not part of the tumor.

Compare with invasive mole, where villi infiltrate myometrium.

Slide 30 · Mitoses: Numerous and sometimes atypical

Proliferative activity supports the malignant interpretation.

Abundant mitotic figures are described.

Some mitoses are abnormal.

Mitotic appearance is interpreted alongside invasion and villous absence.

Slide 31 · Histologic diagnosis is integrative

No single element should be taught in isolation.

Malignant biphasic trophoblast plus absent villi establishes morphology.

Hemorrhage and necrosis reinforce the recognition pattern.

Invasive growth explains clinical behavior.

Slide 32 · Myometrial invasion

SCHEMATIC — not a histologic specimen

Myometrium

Tumor breaches underlying uterine wall

Tumor infiltrates the myometrium.

Invasion is destructive rather than limited to a luminal mass.

The lesion may progress to deep mural involvement.

Slide 33 · Vascular invasion

SCHEMATIC — not a histologic specimen

Myometrium

Vessel lumen

Blood-vessel penetration is frequent

Tumor frequently invades maternal blood vessels.

Vascular access supports hematogenous dissemination.

An aggressive local lesion may already have distant deposits.

Slide 34 · Extent beyond the uterine wall

Advanced direct extension is anatomically possible.

The neoplasm may reach the uterine serosa.

Adjacent structures may be involved in some cases.

This is additional to, not equivalent to, distant hematogenous metastasis.

Slide 35 · Local invasion to systemic dissemination

Causal sequence supported by the invasive and blood-borne behavior described.

Myometrial infiltration

Vascular penetration

Hematogenous metastases

Slide 36 · Typical presentation: Irregular vaginal spotting

The symptom can follow multiple pregnancy scenarios.

Vaginal spotting may be bloody or brown.

It may occur in an apparently normal pregnancy.

It can present after miscarriage or uterine curettage.

Slide 37 · Bleeding character and tissue injury

The characteristic discharge is a clue, not a standalone test.

Discharge of bloody, brown fluid.

Extensive hemorrhage is a dominant gross pathology feature.

Clinical symptoms must be integrated with HCG, history, and pathology.

Slide 38 · Timing of clinical recognition

Latency does not eliminate a gestational relationship.

Pregnancy or pregnancy loss

Curettage / delivery may occur

Symptoms may arise months later

Slide 39 · A normal antecedent pregnancy does not exclude it

Postpartum or postgestational presentation can be misleading.

About 22% follow normal pregnancies (Robbins).

Clinical appearance may be delayed for months.

A pregnancy history remains relevant even without a prior mole.

Slide 40 · HCG is typically markedly elevated

The endocrine signal often supports the clinical suspicion.

Values are typically greater than those seen with hydatidiform moles.

Persistent elevation after a molar pregnancy may suggest ongoing trophoblastic disease.

Absolute thresholds are not specified in the supplied section.

Slide 41 · Low HCG does not exclude choriocarcinoma

Exceptions prevent rigid threshold-based thinking.

Occasional tumors produce relatively little HCG.

Extensively necrotic tumors can have low HCG levels.

Robbins does not define a universal minimum diagnostic concentration.

Slide 42 · HCG interpretation: Common pattern and exception

Typical biochemical pattern

Elevated HCG, often above molar values.

Follow-up after evacuation is relevant.

An elevated level raises concern with compatible findings.

Important exception

Some tumors secrete little HCG.

Extensive tumor necrosis may lower measured HCG.

Low HCG alone cannot refute convincing morphology.

Slide 43 · Postmolar follow-up has a diagnostic purpose

Persistent HCG may signal clinically important residual disease.

After molar evacuation, HCG is followed to nonpregnant levels.

Continued elevation raises concern for invasive mole or choriocarcinoma.

The parent section describes monitoring for 6 months to 1 year.

Slide 44 · HCG in choriocarcinoma versus PSTT

Choriocarcinoma

Usually very elevated HCG.

Some low-HCG exceptions exist.

Marked hemorrhagic, destructive invasion.

Placental site trophoblastic tumor

HCG is moderately elevated.

Mononuclear or binucleated extravillous trophoblasts.

Vascular tropism without similarly destructive hemorrhage.

Slide 45 · Disseminated disease may be present early

Local tumor bulk is not a reliable surrogate for spread.

Widespread metastases are characteristic.

Chest and bone imaging may disclose distant deposits at presentation.

Invasion of blood vessels provides a mechanism for early metastasis.

Slide 46 · Lungs: The most common metastasis

50%

Of choriocarcinoma cases

Hematogenous spread explains lung involvement.

Lungs are the leading metastatic site cited.

The percentage represents the source description; It is not a staging criterion.

Slide 47 · Vagina: Another frequent metastatic site

30–40%

Reported frequency

Vaginal metastasis is especially important to recognize.

It is the second commonest site listed.

It may coexist with metastasis to distant organs.

Slide 48 · Additional sites: Ordered metastatic pattern

Order after lung / vagina

Site

Next

Brain

Next

Liver

Next

Bone

Next

Kidney

Descending order follows the source, which provides no specific percentages for these four sites.

Slide 49 · Hematogenous spread: Clinicopathologic logic

An explanatory schematic; Not a quantitative model of organ-specific probabilities.

Tumor enters vessels

Tumor cells disseminate

Metastases at distant organs

Slide 50 · Clinical evaluation: Imaging of spread

The metastatic pattern informs the reported imaging findings.

Chest imaging may reveal metastatic lesions.

Bone imaging may also detect distant disease.

The source excerpt does not prescribe a particular staging-imaging algorithm.

Slide 51 · Intraplacental choriocarcinoma

A tumor may be present within the placenta during pregnancy.

It may appear as a grossly identifiable placental mass.

It may also be associated with widespread metastatic disease.

This presentation differs from a tumor recognized months after delivery.

Slide 52 · Occult primary tumor hypothesis

A small placental primary may escape recognition at delivery.

Robbins suggests postgestational tumors probably originated in the placenta.

The hypothesis is that small lesions were unrecognized at birth.

This is presented as likely, not as proven for each patient.

Slide 53 · Placental masses require histology

An important pathology practice implication follows.

Intraplacental choriocarcinoma may be grossly visible.

Gross findings alone cannot settle the diagnosis.

Careful histologic examination of placental masses.

Slide 54 · Choriocarcinoma and invasive mole

Choriocarcinoma

No chorionic villi.

Marked destructive hemorrhage and necrosis.

Malignant syncytio- and cytotrophoblasts.

Invasive mole

Hydropic villi persist within invasive lesion.

Villous trophoblast infiltrates uterine wall.

Elevated HCG and vaginal bleeding can overlap.

Slide 55 · Choriocarcinoma and PSTT

Choriocarcinoma

Biphasic cytotrophoblast / syncytiotrophoblast.

Destructive, hemorrhagic invasion.

HCG commonly very high.

PSTT

Mononuclear / binucleated extravillous trophoblast.

Infiltration with less destruction or hemorrhage.

HCG often moderately elevated.

Slide 56 · Choriocarcinoma and ETT

Choriocarcinoma

Two malignant trophoblastic populations.

Prominent vascular and destructive invasion.

High propensity for widespread metastasis.

Epithelioid trophoblastic tumor

Mononuclear trophoblastic tumor cells.

Often abundant clear cytoplasm.

Less overt invasion than PSTT, but can metastasize.

Slide 57 · Four-entity differential: Decisive features

Entity

Villi

Dominant neoplastic cells

Behavior

Invasive mole

Present

Villous trophoblast

Myometrial invasion; emboli possible

Choriocarcinoma

Absent

Cyto- + syncytiotrophoblast

Hemorrhagic vascular invasion

PSTT

Absent

Extravillous mononuclear cells

Vascular tropism; less hemorrhage

ETT

Absent

Mononuclear cells; often clear

Metastatic potential

Villi status and cellular phenotype are pathology-oriented discriminators.

Slide 58 · Therapy depends on stage

The source describes management as stage dependent.

Evacuation of uterine contents is typically part of treatment.

Chemotherapy is the major effective systemic therapy.

No regimen, dosage, or stage algorithm is supplied in the chapter excerpt.

Slide 59 · Broad treatment pathway

Illustrates reported treatment components, not a prescriptive guideline.

Diagnosis and assessment

Uterine evacuation when indicated

Chemotherapy

Slide 60 · Chemotherapy response

Nearly 100%

Remission reported for gestational disease

A notably chemosensitive malignant tumor.

High remission and cure rates.

This does not justify applying the same prognosis to nongestational disease.

Slide 61 · Reproductive outcomes after treatment

Cure often preserves the possibility of future pregnancy.

Many cured patients subsequently have normal pregnancies.

Normal deliveries after cure are reported.

This is a qualitative textbook statement, not an individually predictive rate.

Slide 62 · Nongestational tumors are different

The prognostic comparison is biologically important.

Rare germ-cell-derived tumors may originate in ovary or mediastinum.

They can be histologically indistinguishable from gestational tumors.

Poorer prognosis and more difficult treatment.

Slide 63 · Case A: Bleeding after complete mole

After evacuation of a complete hydatidiform mole, a patient has persistent vaginal bleeding and HCG remains elevated.

Clinical–pathological reasoning

Which trophoblastic entities must be considered?

What histologic finding favors choriocarcinoma over invasive mole?

Slide 64 · Case A: Integrated answer

Persistent postmolar disease has more than one morphologic explanation.

Persistent / invasive mole and choriocarcinoma are both important possibilities.

Hydropic villi within infiltrating tissue favor invasive mole.

Malignant biphasic trophoblast without villi favors choriocarcinoma.

Slide 65 · Case B: Low HCG with a necrotic tumor

A postgestational uterine mass has extensive necrosis and hemorrhage. The HCG elevation is much less marked than anticipated.

Clinical–pathological reasoning

Does a relatively low HCG value exclude choriocarcinoma?

Which morphological features remain critical?

Slide 66 · Case B: Integrated answer

Endocrine behavior has recognized pathological exceptions.

Low hormone output and extensive necrosis are both described exceptions.

Biphasic malignant trophoblast and absence of villi are decisive clues.

Vascular / myometrial invasion supports malignant behavior.

Slide 67 · Case C: A postdelivery placental mass

At delivery, a placental mass is identified. A later examination reveals a trophoblastic neoplasm and distant deposits.

Clinical–pathological reasoning

What rare primary tumor must be considered?

What practice recommendation follows for placental masses?

Slide 68 · Case C: Integrated answer

Intraplacental choriocarcinoma can be clinically consequential.

Choriocarcinoma may originate within the placenta during pregnancy.

It may produce a mass or already disseminated disease.

Placental masses warrant careful histologic examination.

Slide 69 · Integrated disease model

The source-linked conceptual sequence is not an inevitable timeline.

Pregnancy-associated origin

Biphasic villus-free tumor

Hemorrhagic vascular invasion

Hematogenous spread

Slide 70 · Take-home diagnostic synthesis

The smallest useful set of facts is a morphologic–clinical integration.

Pregnancy-associated malignant trophoblast: Syncytio- and cytotrophoblast.

Chorionic villi absent; Necrosis, hemorrhage, mitoses and invasion prominent.

Irregular bleeding, often high HCG, and metastatic spread are characteristic.

Gestational choriocarcinoma is highly chemotherapy responsive.

Slide 71 · References and image provenance

Primary textbook

Robbins, Cotran & Kumar: Pathologic Basis of Disease, 11th ed. (2026), Chapter 22: The Female Genital Tract, pp. 939–942.

Choriocarcinoma section (pp. 940–941); Gestational trophoblastic disease and hydatidiform mole sections (p. 940); tumors of extravascular trophoblasts (p. 942).

Visuals

All diagrams are original editable PowerPoint schematics; no authentic histology or textbook image is reproduced.